https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19261
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19261
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADGlecaprevir / Pibrentasvir may inhibit hepatic transports OATP1B1/B3, P-gp and BCRP and CYP 3A4 and increase plasma concentration of Atorvastatin.
–
–
–
Possible increased risk of HMG CoA inhibitor toxicity.
Avoid association. Choose an alternative.
–
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
–
| Reference number |
|---|
| # patients |
| HCV |
| Dose |
| Frequency |
| Cmax |
| AUC |
| 3373 |
|---|
| 11 |
| - |
| 400/120 mg |
| QD |
| 3373 |
|---|
| 11 |
| - |
| 10 mg |
| QD |
| + 2100% (22x) |
| + 728% (8.3x) |
–